Nyxoah SA

Nyxoah is a medical technology company focused on developing and commercializing therapeutic solutions for obstructive sleep apnea. Its primary product is the Genio system, a leadless hypoglossal neurostimulation device that delivers bilateral stimulation to keep upper airways open during sleep. The system is implanted through a single incision under the chin and operates using an external power source. The company primarily targets adult patients diagnosed with moderate to severe obstructive sleep apnea who cannot tolerate, fail, or refuse positive airway pressure therapies, marketed through hospitals and physicians such as sleep specialists and ear, nose, and throat doctors.

The company operates internationally, commercializing its technology across several European countries, including Germany, Switzerland, Spain, Finland, Austria, England, and the Netherlands, as well as the United States and Abu Dhabi. It maintains subsidiaries in Israel, Australia, the United States, and Germany. Nyxoah is headquartered in Mont-Saint-Guibert, Belgium.

Summary of the business section of Nyxoah's latest annual report, written by StockData.

“As of December 31, 2025, we had over 50 people in our commercial organization in the United States, of which 25 are sales representatives or territory managers that are supported by clinical education specialists, pre-authorization and reimbursement support personnel, customer service, marketing resources and leadership.”